C. Jiang

Immunology · with Chen · 2016

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom C. Jiang trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll

Papers from C. Jiang's perspective

Ordered by how strongly the researchers C. Jiang trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  2. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  3. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
  4. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells (Science Translational Medicine)
  5. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection (Nature Immunology)
  6. PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
  7. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells (Journal of Experimental Medicine)
  8. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (New England Journal of Medicine)
  9. Programmed death ligand-1 expression in non-small cell lung cancer (Laboratory Investigation)
  10. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer (Proceedings of the National Academy of Sciences of the United States of America)

Their papers